Evidence map›Paper›PMID 33197297›Full record

ArticleEuropean journal of haematology2021

The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.

Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J Bahlis, Victor H Jimenez-Zepeda

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Holly LeeDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.ORCID https://orcid.org/0000-0001-8353-0848
Jason TayDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Peter DugganDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Sylvia McCullochDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Paola NeriDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Nizar J BahlisDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Victor H Jimenez-ZepedaDepartment of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.ORCID https://orcid.org/0000-0002-6220-5955
Ontario Institute for Cancer Research · CABaker Hughes (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects. We describe a local experience in providing care for patients with AL amyloidosis and IDD.

methodPatient treatment and disease status since the beginning of the pandemic on March 11, 2020, as declared by WHO, were collected and analyzed.

resultsNinety-six patients with AL amyloidosis and IDD were included. Four patients with IDD and 22 patients with systemic AL amyloidosis were receiving treatment during the pandemic. Since the pandemic, patients' treatments were discontinued if they achieved VGPR or better postinduction. Seven patients discontinued all treatment after achieving VGPR, and others required treatment modifications. 28 patients have been tested for COVID-19, and all tests have been negative. Three patients died since the pandemic, two from organ complications of systemic AL amyloidosis and one from an unrelated cause.

conclusionThe management of AL amyloidosis and IDD must be individualized on the clinical characteristics, centers' access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak.

Indexed as

COVID-19PandemicsSARS-CoV-2AgedAlbertaAntibodies, MonoclonalBasement MembraneBortezomibCOVID-19 TestingCyclophosphamideDexamethasoneDisease ManagementDisease SusceptibilityDrug Therapy, CombinationFemaleHumansAntibodies, MonoclonalBortezomibCyclophosphamidedaratumumabDexamethasoneImmunoglobulin Light ChainsLenalidomideMethylprednisoloneAL amyloidosisCOVID-19immunoglobulin deposition diseaseplasma cell disorder

Identifiers

PMID33197297
PMCPMC7753531
OpenAlexW3106232974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.